Abbas HA et al. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv 2021;5(22):4569-74. Abstract
Abou Dalle I et al. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol 2021;100(12):2957-60. Abstract
Alwash Y et al. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol 2021;96(11):1420-8. Abstract
Bazinet A et al. A phase II study of 5-azacytidine (AZA) and venetoclax as maintenance therapy in patients with acute myeloid leukemia (AML) in remission. ASH 2021;Abstract 2326.
Borate U et al. Comparative outcomes and molecular response predictors of IDH1/2-mutated adult acute myeloid leukemia (AML) patients (pts) after frontline treatment with intensive induction chemotherapy (IC), targeted inhibitors, or hypomethylating agents (HMA) (Alliance). ASH 2021;Abstract 226.
Chen S et al. Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, phase 2 trial. ASH 2021;Abstract 35.
Daver N et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. ASH 2021;Abstract 371.
Daver N et al. Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed/refractory FLT3-mutated acute myeloid leukemia. ASH 2021;Abstract 691.
DiNardo CD et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 2021;22(11):1597-608. Abstract
Kantarjian H et al. Harnessing the benefits from available targeted therapies in acute myeloid leukaemia. Lancet Haematol 2021;8(12):e922-33. Abstract
Kim K et al. A Phase II study of cpx-351 plus venetoclax in patients with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML). ASH 2021;Abstract 1275.
Kim K et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 2021;127(20):3772-81. Abstract
Lachowiez C et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. ASH 2021;Abstract 701.
Lachowiez CA et al. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. ASCO 2021;Abstract 7012.
Maiti A et al. Phase II trial of ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukemia: Updated outcomes in genomic subgroups. ASH 2021;Abstract 694.
Maiti A et al. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 2021; 127(22):4213-20. Abstract
Patel P et al. Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the beat AML master trial. ASH 2021;Abstract 875.
Pollyea DA et al. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax combined with hypomethylating agents. ASH 2021;Abstract 224.
Reville PK et al. Phase II study of venetoclax added to cladribine (CLAD) and low dose AraC (LDAC) alternating with 5-azacytidine (AZA) in older and unfit patients with newly diagnosed acute myeloid leukemia (AML). ASH 2021;Abstract 367.
Rivera D et al. Liposomal cytarabine and daunorubicin (CPX-351) in combination with gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) and post-hypomethylating agent (post-HMA) failure high-risk myelodysplastic syndrome (HR-MDS). ASH 2021;Abstract 2323.
Sasaki K et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol 2022;97(1):68-78. Abstract
Schaefer-Eckart K et al. Immediate allogeneic hematopietic stem cell transplantation for patients with NPM1-mutated AML in molecular relapse. ASH 2021;Abstract 2288.
Tambaro FP et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 2021;35(11):3282-6. Abstract
Tanaka T et al. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood 2021;138(18):1733-9. Abstract
Vachhani P et al. Real-world treatment patterns and outcomes of venetoclax (ven) and hypomethylating agents (HMA) in patients with newly diagnosed acute myeloid leukemia (AML) in the United States. ASH 2021;Abstract 2290.
Venugopal S et al. NPM1 mutations do not retain a favorable prognostic impact in adults with advanced relapsed or refractory (R/R) acute myeloid leukemia (AML). ASH 2021;Abstract 2287.
Venugopal S et al. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 2021;127(19):3541-51. Abstract
Venugopal S et al. Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). ASCO 2021;Abstract 7010.
Wei AH et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J 2021;11(10):163. Abstract
Yilmaz M et al. Hypomethylating agent (HMA) therapy and venetoclax (VEN) with FLT3 inhibitor “triplet” therapy is highly active in older/unfit patients with FLT3 mutated AML. ASH 2021;Abstract 798.
Yilmaz M et al. Quizartinib (quiz) with decitabine (dac) and venetoclax (ven) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML) – RAS/MAPK mutations continue to drive primary and secondary resistance. ASH 2021;Abstract 370.